SCHEMBL7681373

SCHEMBL7681373

CCCC1C(=O)Oc2c(C)c(C(=O)c3ccc(C#N)cc3)n(C)c21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.34
KDM4E B2RXH2 2/20 0.34
GLA P06280 1/20 0.34
HPGD P15428 1/20 0.34
ALOX15 P16050 1/20 0.34
CASP1 P29466 1/20 0.34
CASP7 P55210 1/20 0.34
HSD17B10 Q99714 1/20 0.34
SLC6A3 Q01959 1/20 0.33
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
GRM2 Q14416 1/20 0.33
CA12 O43570 1/20 0.33
CA9 Q16790 1/20 0.33
GAA P10253 1/20 0.32
GRIA2 P42262 1/20 0.32
GRIA4 P48058 1/20 0.32
GSK3B P49841 1/20 0.31
ALDH2 P05091 1/20 0.31
ALDH3A1 P30838 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7674713 0.92 GRM2 (0.39) ALDH1A1KDM4EHPGDALOX15HSD17B10
SCHEMBL7675526 0.86 ABCB11 (0.42) ALDH1A1KDM4EHPGDGAAMAPT
SCHEMBL7674520 0.85 ALDH1A1 (0.37) ALDH1A1CA1CA2CA12CA9
SCHEMBL7678481 0.80 CYP2C19 (0.41) ALDH1A1KDM4EHPGDCA1CA2
SCHEMBL7678014 0.78 ALDH1A1 (0.37) ALDH1A1KDM4ESLC6A3GAADRD2
SCHEMBL7676758 0.78 NPSR1 (0.40) ALDH1A1KDM4EGLA
SCHEMBL7677090 0.76 NOD2 (0.34)
SCHEMBL7677930 0.71 ALDH1A1 (0.34) ALDH1A1SLC6A3CA1CA2CA12
SCHEMBL7682237 0.71 ALDH1A1 (0.40) ALDH1A1HPGDGAAMAPTRAB9A
SCHEMBL7675544 0.70 MEN1 (0.36) ALDH1A1KDM4EHPGDCASP1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6455703-B2 ADMINISTERING EFFECTIVE AMOUNT OF 1,3,6-TRIHYDRO-6-AZA-3-OXAPENTALEN-2-ONE DERIVATIVE TO THE PATIENT FOR INDUCING OR PROMOTING APOPTOSIS AND FOR ARRESTING UNCONTROLLED NEOPLASTIC CELL PROLIFERATION CELL PATHWAYS, INC. 2002-09-24 US disclosed
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia OSI PHARMACEUTICALS, INC. 2001-12-13 US disclosed
US-6160003-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS, INC. (US) 2000-12-12 US disclosed
US-5939417-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS INC (US) 1999-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia MALT1, VHL, CDKN1A ALDH1A1 208/4885KDM4E 1130/4885GLA 1787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.